Esperion Therapeutics (ESPR) – Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Esperion Therapeutics (NASDAQ: ESPR) in the last few weeks:

• 12/18/2024 – Esperion Therapeutics is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $4.00 price target on the stock.
• 12/17/2024 – Esperion Therapeutics is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $8.00 price target on the stock.
• 12/13/2024 – Esperion Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
• 12/12/2024 – Esperion Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
• 12/3/2024 – Esperion Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
• 11/27/2024 – Esperion Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
• 11/19/2024 – Esperion Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
• 11/15/2024 – Esperion Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 11/8/2024 – Esperion Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
• 11/7/2024 – Esperion Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.

Esperion Therapeutics Price Performance

Shares of NASDAQ:ESPR traded down $0.13 during trading on Monday, hitting $2.15. The company had a trading volume of 5,820,467 shares, compared to its average volume of 6,321,606. The stock has a market cap of $423.63 million, a price-to-earnings ratio of -3.36 and a beta of 1.01. The company has a fifty day simple moving average of $2.44 and a two-hundred day simple moving average of $2.20. Esperion Therapeutics, Inc. has a one year low of $1.58 and a one year high of $3.94.

Hedge Funds Weigh In On Esperion Therapeutics

A number of large investors have recently bought and sold shares of ESPR. Wasatch Advisors LP grew its stake in Esperion Therapeutics by 38.4% in the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after acquiring an additional 6,483,070 shares in the last quarter. Marshall Wace LLP grew its stake in Esperion Therapeutics by 94.2% in the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock worth $9,554,000 after purchasing an additional 2,087,635 shares in the last quarter. Bank of New York Mellon Corp raised its position in Esperion Therapeutics by 3,278.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock valued at $1,271,000 after purchasing an additional 555,382 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of Esperion Therapeutics in the 3rd quarter worth $606,000. Finally, Inspire Investing LLC bought a new position in shares of Esperion Therapeutics during the 2nd quarter worth $758,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.